Cargando…
P013: Outcomes of first-line treatment (FL) of classical Hodgkin lymphoma (cHL) in Argentina: a real life multicenter retrospective study
Autores principales: | Laura, Korin, Otero, Victoria, Mahuad, Carolina, Martinez, Enriqueta, Warley, Fernando, Rivello, Hernan García, Cristaldo, Nancy, Kohan, Dana, Garate, Gonzalo, De Los Angeles Vicente Reparaz, Maria, Florencia Aizpurua, Maria, Bilbao, Erica Rojas, Cerana, Susana, Funes, María Eugenia, Plaza, Iliana, Foncuberta, Cecilia, Baron, Anahi Vijnovich, Cranco, Santiago, Vitriu, Adriana, Gomez, Mariela, Lavalle, Justina, Casali, Claudia, Clavijo, Manuela, Melillo, Luciana, Cabral Lorenzo, Maria Cecilia, Miroli, Augusto, Fishman, Laura, Pavlove, Maximiliano, Miodosky, Marcela, Cugliari, Silvana, Zerga, Marta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621555/ http://dx.doi.org/10.1097/01.HS9.0000890620.44386.15 |
Ejemplares similares
-
Retrospective Multicenter Real-Life Study on the First-Line Treatment of Classical Hodgkin Lymphoma in Argentina
por: Mahuad, Carolina, et al.
Publicado: (2022) -
P041: Low percentage of T lymphocytes in Hodgkin’s Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status
por: Korin, Laura, et al.
Publicado: (2022) -
P004: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials
por: Viviani, Simonetta, et al.
Publicado: (2022) -
Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib
por: Mahuad, Carolina Valeria, et al.
Publicado: (2016) -
P1275: PERCENTAGE OF TUMOR INFILTRATING T LYMPHOCYTES MEASURED BY FLOW CYTOMETRY AT DIAGNOSIS PREDICTS SURVIVAL AFTER SALVAGE CHEMOTHERAPY IN RELAPSED/ REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA PATIENTS.
por: Korin, L., et al.
Publicado: (2022)